Please login to the form below

Not currently logged in
Email:
Password:

Medivir appoints Actelion's Henric Juserius to senior commercial role

As executive vice president, commercial he will head up all the company's activities in the area

Medivir has appointed Actelion's Henric Juserius to head up its commercial activities and join its management team.

Juserius will move to the Swedish specialty pharma company in August from Actelion, where he was most recently commercial director for the Nordic region.

He has more than 20 years' experience in pharmaceutical marketing and sales, gained from companies such as Astra, GlaxoWellcome, Pfizer, Serono and Actelion.

Maris Hartmanis, Medivir's president and CEO, said: "I am very pleased to welcome Henric Juserius to Medivir as executive vice president, commercial.

“His extensive experience and broad expertise in marketing and sales of prescription drugs from both large and small pharmaceutical companies will be invaluable now that Medivir is approaching a market launch in the Nordic countries of its flagship product for hepatitis C, TMC435.”

The drug is a novel protease inhibitor in phase III clinical trials for hepatitis C that Medivir is developing in collaboration with Janssen Pharmaceuticals.

Meanwhile, the firm's first product, OTC cold sore treatment Xerese/Xerclear, is approved in Europe, where Medivir is launching it in partnership with GlaxoSmithKline.

15th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics